Capitalizing on Opportunities in Cord Blood Industry Growth

2013-04-02
Published : Apr-2013

The recently launched industry report “Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)” reveals strategies for dominating the cord blood banking industry, investigates tactics for global expansion, identifies patterns in regional dominance, and explores methods for investing in the sector.

The report is designed to guide decision-making of global cord blood banks, as well as to advise companies investing in the cord blood banking sector, including venture capital funds and private investors. It differs from the “Complete 2012-13 U.S. Cord Blood Banking Industry Report” (details here) in that it is a strategic overview of how to profit from the global cord blood banking market, rather than from the U.S. markets alone.

Stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer.  Additionally, cord blood banks now exist in nearly every developed country, as well as several developing nations. However, there is still significant variation within the industry.

Buy a copy of this report @ http://www.reportsnreports.com/reports/10596-capitalizing-on-opportunities-in-cord-blood-industry-growth.html

First, there is the divide between private and public cord blood banking, in which private companies serve individual families, while public banks serve the broader public.  Additionally, some cord blood banks receive only units from nearby hospitals and birthing centers, while others allow mail-in units from a wide geographic region.  There is also variation in the services offered by private cord blood banks, with cord tissue storage emerging as a commercial service in 2010, when the Cord Blood Registry began offering it, to complement its cord blood banking services. This trend of cord tissue storage has had a significant impact on the cord blood banking industry, with nine private U.S. companies now offering the service. Finally, there is also significant variation in the quality, pricing, and guarantees promised by cord blood banks.

Despite this variation, as of 2013, the cord blood banking industry remains one of the fastest growing industries in the world. In 2005, there were only 23 active cord blood banks worldwide; today there are 485. This represents a 21-fold increase (2,100%) in industry growth, over only a seven year period.

Over the past 12 months alone, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood industry and revenue growth at existing operations. Deeper analysis reveals that most existing cord blood banks follow a bi-modal distribution, either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (25% or more per annum).  To guide industry competitors, this report considers the questions:

  • What factors are causing a substantial number of new cord blood banks to open up business?
  • What will be the effect of these new entrants to the cord blood banking industry for existing competitors?
  • How can existing competitors maintain a position of dominance in the industry among this trend?

Request a Sample of complete report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=10596

While a similar bimodal distribution existed in the prior 12 month period (trailing 12 to 24 months), the peaks have continued to separate over the past 12 months, with the average flat-growth company staying stagnant and the average fast- growth company substantially increasing its per annum growth rate. This trend indicates an increasing shift in dominance toward fast-growth companies, which begs the questions:

  • What are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively building revenue?
  • Why are the fast-growth companies continuing to increase their dominance relative to the flat growth companies?

Additionally, there has been rapid industry growth within specific regions of the world. The updated report reveals the models and tactics used within those regions in order to identify strategies that businesses in other regions should consider leveraging as approaches for growth. It also includes a global survey of expectant parents that explores how cord blood banks can best communicate with and market services to potential clients.

Contact [email protected] for more details.

 

 

Filed in: Biotechnology
More Reports
Title Price Buy Now

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User – Global Forecast to 2027

“The stem cell assays market growth can be attributed to factors such as the rising demand for technologically advanced stem cell analysis instruments, increase in the prevalence of cancer & other diseases and rising number of biopharma and & biotechnology companies working on stem cell based therapies.” The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies. The viability/cytotoxici......
$

Nucleic Acid Isolation & Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Diagnostics), End User (Pharma, Biotech) – Global Forecast to 2027

The nucleic acid isolation and purification market is expected to grow at a CAGR of 7.9% in the forecast period. The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies, improving regulatory and reimbursement scenario, and the growing adoption of molecular diagnostics and personalized medicines are expected to offer a wide range of growth opportunities for players in the market. However, the high cost of automated instruments is expected to hinder the growth of the market. As the world be......
$4950

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

“Rising number of road accidents and associated traumatic wounds and growing incidence of burn injuries are driving the overall growth of the wound care biologics market” The global wound care biologics market is valued at an estimated USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as the growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market. “The biological skin substitutes segment accounted for the highest growth rate in the wound care biologics ma......
$4950

Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) – Global Forecast to 2027

“The global bioanalytical testing services market is projected to grow at a CAGR of 15.6%” Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products. Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period. “The Cell-based assays segment is expected to account for the largest share of the bioanalytical testing services market” The increasing prevalence of chronic diseases and the rising number of clinical trials ar......
$4950

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) – Global Forecast to 2027

“Single-cell analysis segment has gained significant traction in the recent years attributed to the widening applications of this technology in cancer research. This is further supplemented by the robust government initiatives targeted towards single-cell analysis research. The growth of the single-cell analysis segment is expected to drive the overall growth of the cell analysis market.” The global cell analysis market is projected to reach USD 28.6 Billion by 2027 from USD 17.7 Billion in 2022, at a CAGR of 10.1% during the forecast period. Key opportunities for the cell analysis market include, emerging economies, high risk of communicable diseases and pandemic outbreak, and increasing adoption of novel cellular assays in various cancer research applications. On the other hand, h......
$4950

3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region – Global Forecast to 2027

“Increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine is driving the overall growth of the3D Cell culture market” The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period. The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the f......
$4950

Tangential Flow Filtration Market by Product (System, Membrane Filter), Material (PES, PVDF, PTFE), Technique (Ultrafiltration), Application (Final Product Processing, Raw Material Filtration), End User (Pharma, Biotech), Region – Global Forecast to 2027

“Growth in the tangential flow filtration market can be attributed to factors such as the growing advantages of tangential flow filtration over normal flow filtration, rising R&D spending in pharmaceutical & biotechnology industries and increasing adoption of single-use technologies.” The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period. The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the s......
$4950

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) – Global Forecast to 2029

“Increased focus on human microbiome therapy development to drive the growth of this market.” The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth. “By product segment, the drugs segment accounted for the largest share of huma......
$4950

Exosome Research Market by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User – Global Forecast to 2026

“Increasing interest in exosome-based proceduresto Drive the Growth of Market” The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. “By product & service, the kits & reagents segment accounted for the largest share of the exosome research market” Based on product and service, the exosomes market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other ki......
$4950

Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) – Global Forecast to 2027

“Continuous technological innovations in NGS platforms is the key factors driving growth in the metagenomic sequencing market’’ The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. “By technology segment, the shotgun metagenomic sequencing segment accounted for the fastest-growing segment of the metagenomic sequencing market” Based on technol......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy